|
業務類別
|
-- |
|
業務概覽
|
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain. |
| 公司地址
| 100 Pine Street, Suite 500, San Francisco, CA, USA, 94111 |
| 電話號碼
| +1 415 512-7740 |
| 傳真號碼
| -- |
| 公司網頁
| http://www.adynxx.com |
| 員工數量
| 81 |
| Mr. Rick Orr |
Director, Chief Executive Officer and Principal Financial Officer |
-- |
31/05/2019 |
| Dr. Donald C. Manning, M.D.,PhD |
Chief Medical Officer |
-- |
09/05/2019 |
| Dr. Julien Mamet, PhD |
Chief Scientific Officer and Director |
-- |
09/05/2019 |
| Ms. Dina Gonzalez |
Controller and Principal Accounting Officer |
-- |
31/05/2019 |
|
|
| Mr. Dennis G. Podlesak |
Director |
09/05/2019 |
| Dr. Eckard Weber,M.D. |
Director |
09/05/2019 |
| Gregory J. Flesher |
Director |
22/07/2019 |
| Mr. Rick Orr |
Director, Chief Executive Officer and Principal Financial Officer |
31/05/2019 |
| Dr. Julien Mamet, PhD |
Chief Scientific Officer and Director |
09/05/2019 |
| Mr. Stan E. Abel |
Director |
09/05/2019 |
| Mr. Matthew Ruth |
Director |
09/05/2019 |
|
|
|
|
